Rigel Pharmaceuticals (FRA:RI2) Total Operating Expense: €133.5 Mil (TTM As of Mar. 2026)


FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
76 GF Score
Price €33.44
GF Value €24.49
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Total Operating Expense?

Rigel Pharmaceuticals FRA:RI2 -0.45% 76 Total Operating Expense is €133.5 Mil as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 76/100 and a GF Value™ of €24.49. The stock has 7 warning signs investors should review.

Rigel Pharmaceuticals's Total Operating Expense for the three months ended in Mar. 2026 was €36.6 Mil. Rigel Pharmaceuticals's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €133.5 Mil.

Rigel Pharmaceuticals Total Operating Expense Related Terms

Rigel Pharmaceuticals Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Total Operating Expense Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.06 163.05 119.45 130.30 127.41

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.44 31.28 30.92 34.74 36.61
FRA:RI2
76GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €133.5 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €133.5 Mil mean?
Rigel Pharmaceuticals (FRA:RI2) has a Total Operating Expense of €133.5 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rigel Pharmaceuticals and its competitors.
Is Rigel Pharmaceuticals' Total Operating Expense too high?
Rigel Pharmaceuticals' current Total Operating Expense is €133.5 Mil. Overall, Rigel Pharmaceuticals has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Total Operating Expense compare to CADL and IMMX?
Rigel Pharmaceuticals' Total Operating Expense of €133.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Rigel Pharmaceuticals and its competitors. Rigel Pharmaceuticals's current Total Operating Expense is €133.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Total Operating Expense of €133.5 Mil. The stock's GF Value™ is €24.49, compared to a current price of €33.44 — trading 36.5% above its estimated fair value. The current Total Operating Expense is €133.5 Mil. Rigel Pharmaceuticals' overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Total Operating Expense is €133.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €33.44 is trading 36.5% above its estimated GF Value™ of €24.49.

Key valuation signals for FRA:RI2:

  • Total Operating Expense: €133.5 Mil
  • GF Value™: €24.49 vs. price of €33.44 (36.5% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
76GF Score

Get the complete analysis for FRA:RI2

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.44
Price
€24.49
GF Value